Combination intravenous formulation of acetaminophen and ibuprofen approved; recommendations from the ADA for dealing with acute dental pain; RSV vaccine under review for younger age group; Gilead call halt on investigational leukemia treatment; athlete’s foot spray recalled.
Biogen discontinue Alzheimer treatment; The American Academy of Dermatology issue new acne vulgaris management guidelines; Update for ongoing Paxlovid availability; Narcolepsy/ADHD treatment recalled; FDA warn against copycat eye drop products.
T-cell malignancies prompt label changes for certain T-cell immunotherapies; Novel opioid provides in-built protection against overdose; Hypocalcemia risk with Prolia; At-Home semen insemination kit cleared; New asthma rescued medicine approved
Gene therapy approved for β-thalassemia; treatment for preventing of chronic inflammatory demyelinating polyneuropathy relapse; device to aid dermatologist referrals; vertebral strength device for low-bone mass; Narcan shelf-life extension
Researchers examine the link between diabetes, obesity treatments and suicidal ideation; topical treatment for molluscum contagiosum; IV bags recalled following discovery that they may contain twice as much of the labeled drug; update on penicillin shortage; newly cleared test measures HbA1c from menstrual blood.
Expert panel rank the 30 best diets for 2024; Counterfeit Ozempic on the rise; A new Myasthenia gravis treatment has been approved; Herpes tests may produce false positives; Safety concerns over IV promethazine hydrochloride.
Topical gel approved to treat partial thickness wounds in epidermolysis bullosa; Priority Review given to 21-valent pneumococcal conjugate vaccine; sensory and motor stimuli video game for ADHD gains expanded age approval; on-demand HIV prevention for women; multiple food allergy drug accepted for priority review.
The ADA release their 2024 guidance for the management of diabetes; a new blood collection device obtains lab-quality samples using a the finger; novel treatment for postpartum depression becomes available; a study for a male birth control pill begins; and a Public Benefit Corporation seeks approval for an MDMA-assisted therapy.
Novel weight loss treatment now available in pharmacies; Novo Nordisk warns about the risks of compounded semaglutide; treatment approved for paroxysmal nocturnal hemoglobinuria; over-the-counter insemination kit cleared by the FDA.
Safety alert issued for serious reactions to certain seizure drugs; drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.
Please login or register first to view this content.
